Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare <i>EGFR</i> mutations
Shinnosuke Ikemura(Keio University), Kenzo Soejima(Keio University), Tadashi Manabe(Keio University), Katsuya Tsuchihara(Chiba Cancer Center), Biao Ma(Foundation for Biomedical Research and Innovation), Mitsugu Araki(Kyoto University), Takashi Kohno(Gunma University), Keigo Kobayashi(Osaka Gakuin University), Kōichi Goto(National Cancer Center Hospital East), Keita Masuzawa(Kitasato Institute Hospital), Sachiyo Mimaki(Translational Research in Oncology), Yasushi Okuno(Kyoto University), Yuichiro Hayashi(Keio University), Kiyotaka Yoh(National Cancer Center Hospital East), Kota Ishioka(Keio University), Ichiro Nakachi(Saiseikai Utsunomiya hospital), Susumu Kobayashi(Beth Israel Deaconess Medical Center), Ho Namkoong(Keio University), Morio Nakamura(Saiseikai Central Hospital), Daisuke Arai(Keio University), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Junko Hamamoto(Keio University), Fumie Ono(Kyoto University), Ichiro Kawada(Keio University), Katsuhiko Naoki(Broad Institute), Shingo Matsumoto(National Cancer Center Hospital East), Mayumi Kamada(Kyoto University), Ryo Kanada
Cited by 54
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
|Nature Immunology|2020|810